Display options
Cite
López-Pérez A, Norlin S, Steneberg P, et al. Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice. Sci Rep. 2021;11(1):24410doi: 10.1038/s41598-021-03567-3.
López-Pérez, A., Norlin, S., Steneberg, P., Remeseiro, S., Edlund, H., & Hörnblad, A. (2021). Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice. Scientific reports, 11(1), 24410. https://doi.org/10.1038/s41598-021-03567-3
López-Pérez, Ana, et al. "Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice." Scientific reports vol. 11,1 (2021): 24410. doi: https://doi.org/10.1038/s41598-021-03567-3
López-Pérez A, Norlin S, Steneberg P, Remeseiro S, Edlund H, Hörnblad A. Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice. Sci Rep. 2021 Dec 23;11(1):24410. doi: 10.1038/s41598-021-03567-3. PMID: 34949756; PMCID: PMC8702551.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2021 Dec 23;11(1):24410. doi: 10.1038/s41598-021-03567-3.

Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice.

Scientific reports

Ana López-Pérez, Stefan Norlin, Pär Steneberg, Silvia Remeseiro, Helena Edlund, Andreas Hörnblad

Affiliations

  1. Umeå Centre for Molecular Medicine (UCMM), Umeå University, Johan Bures väg 12, 90187, Umeå, Sweden.
  2. Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, 90187, Umeå, Sweden.
  3. Umeå Centre for Molecular Medicine (UCMM), Umeå University, Johan Bures väg 12, 90187, Umeå, Sweden. [email protected].
  4. Umeå Centre for Molecular Medicine (UCMM), Umeå University, Johan Bures väg 12, 90187, Umeå, Sweden. [email protected].

PMID: 34949756 PMCID: PMC8702551 DOI: 10.1038/s41598-021-03567-3

Abstract

AMP-activated protein kinase (AMPK) has an important role in cellular energy homeostasis and has emerged as a promising target for treatment of Type 2 Diabetes (T2D) due to its beneficial effects on insulin sensitivity and glucose homeostasis. O304 is a pan-AMPK activator that has been shown to improve glucose homeostasis in both mouse models of diabetes and in human T2D subjects. Here, we describe the genome-wide transcriptional profile and chromatin landscape of pancreatic islets following O304 treatment of mice fed high-fat diet (HFD). O304 largely prevented genome-wide gene expression changes associated with HFD feeding in CBA mice and these changes were associated with remodelling of active and repressive chromatin marks. In particular, the increased expression of the β-cell stress marker Aldh1a3 in islets from HFD-mice is completely abrogated following O304 treatment, which is accompanied by loss of active chromatin marks in the promoter as well as distant non-coding regions upstream of the Aldh1a3 gene. Moreover, O304 treatment restored dysfunctional glucose homeostasis as well as expression of key markers associated with β-cell function in mice with already established obesity. Our findings provide preclinical evidence that O304 is a promising therapeutic compound not only for T2D remission but also for restoration of β-cell function following remission of T2D diabetes.

© 2021. The Author(s).

References

  1. J Clin Invest. 2019 Jul 2;129(10):4124-4137 - PubMed
  2. Bioessays. 2011 Aug;33(8):582-7 - PubMed
  3. J Clin Invest. 1992 Jul;90(1):77-85 - PubMed
  4. Lancet Diabetes Endocrinol. 2018 May;6(5):361-369 - PubMed
  5. Acta Endocrinol (Copenh). 1988 Jul;118(3):365-73 - PubMed
  6. Nat Rev Endocrinol. 2018 Feb;14(2):88-98 - PubMed
  7. Elife. 2014 Sep 16;3:e02809 - PubMed
  8. J Clin Invest. 2019 Oct 1;129(10):4001-4008 - PubMed
  9. Methods Mol Biol. 2013;1067:105-24 - PubMed
  10. Nat Commun. 2016 Aug 30;7:12631 - PubMed
  11. Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5 - PubMed
  12. EMBO J. 2012 May 2;31(9):2090-102 - PubMed
  13. Cell Metab. 2019 Jul 2;30(1):129-142.e4 - PubMed
  14. Pflugers Arch. 2010 Jun;460(1):69-76 - PubMed
  15. OMICS. 2012 May;16(5):284-7 - PubMed
  16. Annu Rev Nutr. 2016 Jul 17;36:45-71 - PubMed
  17. Genome Biol. 2014;15(12):550 - PubMed
  18. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9953-7 - PubMed
  19. Cell Metab. 2018 Oct 2;28(4):547-556.e3 - PubMed
  20. Nat Commun. 2018 Feb 2;9(1):485 - PubMed
  21. Ann Surg. 1982 Oct;196(4):389-99 - PubMed
  22. Cell. 2008 Aug 8;134(3):405-15 - PubMed
  23. Science. 1990 Oct 26;250(4980):546-9 - PubMed
  24. Mol Cell. 2017 Jun 15;66(6):789-800 - PubMed
  25. Front Genet. 2017 Apr 10;8:41 - PubMed
  26. Diabetes. 2017 Aug;66(8):2175-2187 - PubMed
  27. Nat Genet. 1997 Nov;17(3):327-30 - PubMed
  28. Diabetologia. 2011 Oct;54(10):2506-14 - PubMed
  29. Mol Metab. 2020 May;35:100959 - PubMed
  30. Cell. 2012 Sep 14;150(6):1223-34 - PubMed
  31. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  32. Nat Biotechnol. 2012 Feb 26;30(3):261-4 - PubMed
  33. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5208-13 - PubMed
  34. Genome Biol. 2008;9(9):R137 - PubMed
  35. Nat Methods. 2012 Mar 04;9(4):357-9 - PubMed
  36. Bioinformatics. 2015 Jul 15;31(14):2382-3 - PubMed
  37. JCI Insight. 2018 Jun 21;3(12): - PubMed
  38. Bioinformatics. 2013 Jan 1;29(1):15-21 - PubMed
  39. BMC Bioinformatics. 2010 May 11;11:237 - PubMed
  40. Metabolism. 1997 Jan;46(1):97-106 - PubMed
  41. Nat Rev Mol Cell Biol. 2018 Feb;19(2):121-135 - PubMed
  42. J Endocrinol. 2018 Feb;236(2):R109-R143 - PubMed
  43. Diabetes. 2014 Jun;63(6):1994-2005 - PubMed
  44. Diabetes. 2021 Sep;70(9):2058-2066 - PubMed
  45. Cell Rep. 2013 Sep 26;4(6):1262-75 - PubMed
  46. J Clin Endocrinol Metab. 2016 Mar;101(3):1044-54 - PubMed

Publication Types